Skip to main content
Clinical Trials/DRKS00025852
DRKS00025852CompletedNot Applicable

Survival analysis of Acid Sphingomyelinase deficiency (ASMD) among German patients during childhood to adulthood: a retrospective chart review study - SURGE

Sanofi Genzyme0 sites33 target enrollmentStarted: July 26, 2021Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
33

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
one to one (—)
Sex
All

Inclusion Criteria

  • I 01.Pediatric, adolescent and adult ASMD (surviving and deceased) patients with retrievable information from German hospital medical records between January 1st 1990 and July 31st 2021.
  • I 02.A first date of evidence of ASMD defined as either first symptom onset or a diagnosis of ASMD Type B or A/B, whichever comes first. This first date of evidence of ASMD to be defined as the index date.
  • I 03.Patient and/or patient’s parent/legal guardian must provide informed assent/consent.

Exclusion Criteria

  • E 01. Patients with no retrievable information from the medical record
  • E 02. Patients with ASMD type A

Investigators

Similar Trials